3-chloro-6-trifluoromethyl-pyridazine is an important trifluoromethylated heterocycle building block for the synthesis of various pharmaceutical products, e.g. Therapeutic agents for diabetes, Fast dissociating dopamine 2 receptor antagonists, NPY Y5 receptor antagonists, GlyT1 inhibitors and ATR kinase inhibitors, etc..
Concise synthesis of ω-fluoroalkylated ketoesters. A building block for the synthesis of six-, seven-, and eight-membered fluoroalkyl substituted 1,2-diaza-3-one heterocycles. 
Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methyl ethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. 
Exploration of a new series of CCR5 antagonists: Multi-dimensional optimization of a sub-series containing N-substituted pyrazoles. 
Copper-mediated trifluoromethylation of heteroaromatic compounds by trifluoromethyl sulfonium salts. 
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. 
Enantioselective synthesis of BMS-911278: a triple reuptake inhibitor. 
Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain. 
 W.wan, et al, Tetrahedron, 2009, 65(21), pp 4212-4219.
 E.Pinard, et al, J. Med. Chem., 2010, 53(12), pp 4603-4614.